北陆药业获得枸橼酸西地那非口崩片《药品注册证书》

Core Viewpoint - Beilu Pharmaceutical (300016.SZ) has received the drug registration certificate for Sildenafil Citrate Orally Disintegrating Tablets from the National Medical Products Administration, indicating a significant advancement in its product portfolio [1] Company Summary - Beilu Pharmaceutical has announced the approval of Sildenafil Citrate Orally Disintegrating Tablets, a formulation designed for the treatment of erectile dysfunction [1] - The orally disintegrating form of sildenafil offers advantages such as rapid onset of action and confirmed efficacy, catering to patient needs for convenience and privacy [1] Industry Summary - Sildenafil, a selective inhibitor of phosphodiesterase type 5, is widely recognized for its effectiveness in treating erectile dysfunction [1] - The orally disintegrating tablet form, developed by Pfizer, was approved for importation into China in 2019, highlighting the growing demand for innovative drug delivery methods in the market [1]